Publication date context February 19 2026. A ClinicalTrials.gov record points to a new ALS related trial evaluating a device for inspiratory muscle training alongside a sham control. Sponsored by University Ramon Llull, the study aims to assess a medical device intended to support respiratory muscles in people living with amyotrophic lateral sclerosis. The trial is listed as recruiting, signaling ongoing regulatory interest in device based therapies to support breathing in neurodegenerative disease. This article presents the publicly available information in a regulatory oriented context, noting the trial type, design and status for clinicians, patients and device developers.
What changed and why it matters for ALS care?
The entry identifies a prospective study comparing inspiratory muscle training with sham training as an investigational device. While the specific device is not described in detail in the source, the intervention category reflects a device guided effort to train inspiratory muscles, a framework that may influence regulatory discussions on safety, effectiveness and training protocols in ALS care.
Who is affected by this trial?
Participants are people with amyotrophic lateral sclerosis, a condition associated with progressive respiratory muscle weakness. Regulators and clinicians may watch recruitment patterns as an indicator of interest in respiratory device based therapies for ALS.
How does the device work in this study?
The study uses an inspiratory muscle training device versus sham training. The exact mechanism and device specifications are not described in the available record. The regulatory context will focus on intended use, performance and safety with clear comparators and outcome measures.
What is the status and oversight of the trial?
According to the record, the trial is actively recruiting. Oversight and regulatory compliance will follow standard practices for device trials including informed consent and monitoring for adverse events. The sponsor is University Ramon Llull and the trial identifier is NCT07413718.
Safety and regulatory considerations what is known and what remains?
Publicly available data do not provide detailed safety findings. As with any device study, regulators will review training protocols, device safety data and patient monitoring plans as part of trial reporting and potential future submissions.
Conclusion what this means for stakeholders
For device makers, investigators and clinicians this ALS trial highlights regulatory friendly pathways for testing respiratory devices in neuro degenerative disease. The existence of a sham control aids in interpretation of outcomes and strengthens the evidentiary basis for future regulatory submissions. Stakeholders should monitor the ClinicalTrials.gov page for updates on recruitment and results.
Announcement line
For full information about the announcement see the link below.
https://clinicaltrials.gov/study/NCT07413718?term=medical+devicehttps://clinicaltrials.gov/study/NCT07413718?term=medical+device